Exelixis Earnings: What Investors Should Watch

Exelixis (NASDAQ:EXEL) will report earnings after markets close on Tuesday, May 7th. Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The Company is building a portfolio of compounds it believes could become pharmaceutical products. Exelixis has strategic alliances with pharmaceutical and biotechnology companies.

Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a loss of $0.27 to a loss $0.3. For the current year, the average estimate is a loss of $1.24, which is worse than the estimate ninety days ago.